ArticleArthritis and rheumatism2013
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
Article in Arthritis and rheumatism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- T cell Dissimilarities in B Cell Activating Factor-Deficient Versus B Cell Activating Factor Receptor 3-Deficient Systemic Lupus Erythematosus-Prone NZM 2328 Mice as Contributors to Their Divergent Clinical Outcomes.ACR open rheumatology · 2024Article
- Inhibition of B cell activation followingJournal of translational autoimmunity · 2021Article
- Essential role and therapeutic targeting of the glomerular endothelial glycocalyx in lupus nephritis.JCI insight · 2020Article
- BAFF inhibition in SLE-Is tolerance restored?Immunological reviews · 2019Review
- Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.JCI insight · 2018Article
- Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse.Scientific reports · 2018Article
- An update on lupus animal models.Current opinion in rheumatology · 2017Review
- Haploinsufficiency of NADPH Oxidase Subunit Neutrophil Cytosolic Factor 2 Is Sufficient to Accelerate Full-Blown Lupus in NZM 2328 Mice.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.European journal of immunology · 2017Article
- Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.Drug design, development and therapy · 2017Review
- The BAFFling effects of rituximab in lupus: danger ahead?Nature reviews. Rheumatology · 2016Review
- Expression of BAFF and BR3 in patients with systemic lupus erythematosus.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016Article
- Article
- Epidermal injury promotes nephritis flare in lupus-prone mice.Journal of autoimmunity · 2015Article
- The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man.Arthritis research & therapy · 2015Review
- BAFF regulates follicular helper t cells and affects their accumulation and interferon-γ production in autoimmunity.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Effect of TACI signaling on humoral immunity and autoimmune diseases.Journal of immunology research · 2015Review
- The BAFF/APRIL system in SLE pathogenesis.Nature reviews. Rheumatology · 2014Review
- Future prospects in biologic therapy for systemic lupus erythematosus.Nature reviews. Rheumatology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE).
methodsBcma-, Taci-, and Br3-null mutations were introgressed into NZM 2328 mice. NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice were evaluated for lymphocyte phenotype and BAFF receptor expression by flow cytometry; for B cell responsiveness to BAFF by in vitro culture; for serum levels of BAFF and total IgG and IgG anti-double-stranded DNA (anti-dsDNA) by enzyme-linked immunosorbent assay; for renal immunopathology by immunofluorescence and histopathology; and for clinical disease.
resultsBCMA, TACI, and B lymphocyte stimulator receptor 3 (BR3) were not surface-expressed in NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice, respectively. Transitional and follicular B cells from NZM.Br3-/- mice were much less responsive to BAFF than were the corresponding cells from wild-type, NZM.Bcma-/-, or NZM.Taci-/- mice. In comparison with wild-type mice, NZM.Bcma-/- and NZM.Taci-/- mice harbored an increased number of spleen B cells, T cells, and plasma cells, whereas serum levels of total IgG and IgG anti-dsDNA were similar to those in wild-type mice. Despite their paucity of B cells, NZM.Br3-/- mice had an increased number of T cells, and the numbers of plasma cells and levels of IgG anti-dsDNA were similar to those in wild-type mice. Serum levels of BAFF were increased in NZM.Taci-/- and NZM.Br3-/- mice but were decreased in NZM.Bcma-/- mice. Despite their phenotypic differences, NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/- mice had renal immunopathology and clinical disease that were at least as severe as that in wild-type mice.
conclusionAny single BAFF receptor, including BR3, is dispensable for the development of SLE in NZM mice. Development of disease in NZM.Br3-/- mice demonstrates that BAFF-BCMA and/or BAFF-TACI interactions contribute to SLE, and that a profound, life-long reduction in the numbers of B cells does not guarantee protection against SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.